The Major Applications of Kinase Activity Assays
Sunday, 20 November 2016
When it comes to the significant process that is compiling components for the correct kinase assay for your work, it can be extremely time-consuming and expensive. Having a simple mix-and-read method can take a lot of the stress out of this process. The good news is that you can find a kinase assay kit which
- Published in HTS Assays
No Comments
BellBrook Labs Awarded NIH Grant to Validate New Target for Liver Fibrosis Using Transcreener GTPase Assay Platform
Wednesday, 09 November 2016
BellBrook Labs was awarded a Phase I Small Business Innovative Research (SBIR) grant of $353,000 from the National Institute on Alcohol Abuse and Alcoholism for pharmacological validation of GIV, a nonreceptor guanine nucleotide exchange factor (GEF), as a therapeutic target for liver fibrosis. BellBrook will use proprietary high throughput GTPase assay methods to identify small
Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part II
Wednesday, 19 October 2016
In Part I of II in this blog series, discussion included the challenges of screening methyltransferases, steps in developing an SAH assay, the experimental assay procedure, assay sensitivity, and reagent stability. Please view the previous post here: Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part I. Compatibility with Diverse MT Accepter Substrates As
- Published in Epigenetics, HTS Assays, Products
ICBS Conference 2016
Thursday, 06 October 2016
Location: Madison, WI Date: October 24-26 BellBrook Labs’ team of scientists will be presenting the following posters at the International Chemical Biology Society. A Homogenous, Universal Methyltransferase Assay Based on a Microbial Riboswitch Leveraging Aptamers for Detection of Growth Factors in an HTS Compatible Format: An AptaFluor™ VEGF Assay Measuring Drug Residence Times
Posters and Presentations from DOT 2016
Friday, 30 September 2016
Did you miss the DOT 2016 meeting in Boston or would like a recap? View the posters and presentations from BellBrook’s scientists below. Posters: Aptamer Based Homogenous Single-Reagent HTS Assay Platform for Human Growth Factors Aniket, Elizabeth Vu, Meera Kumar, Tom Zielinski, Justin Brink, and Robert G. Lowery Determination of Drug Residence Time in a
Creating a Methyltransferase HTS Assay Using an SAH Riboswitch Part I
Friday, 23 September 2016
Riboswitches were discovered in 2002 by Ron Breaker at Yale as RNA-based intracellular sensors of vitamin derivatives. During the last decade, riboswitches have been identified that bind a range of small biomolecules including nucleotides, amino acids, and ions. Riboswitches exert regulatory control of transcription, translation, splicing, and RNA stability. BellBrook scientists used a riboswitch that
- Published in Epigenetics, HTS Assays, Products
BellBrook Labs Receives NIH Funding to Commercialize Methyltransferase Assays for Epigenetic Drug Discovery
Tuesday, 30 August 2016
BellBrook Labs has been awarded an $860,000 Phase II SBIR grant from the National Institutes of General Medical Sciences to develop an innovative methyltransferase assay for epigenetic drug discovery. The company’s scientists engineered a fluorescent light switch into a bacterial metabolite sensor to leap-frog the limitations of conventional reagents. Madison, WI – August 31, 2016
- Published in Company, Epigenetics, News
Discovery on Target Conference 2016
Wednesday, 17 August 2016
Discovery on Target 2016 September 19-22 Westin Boston Waterfront Boston, MA Exhibition Visit Booth #24 to: Discuss BellBrook’s current HTS assays. Share your thoughts on the future of drug discovery. Learn about upcoming AptaFluor™ HTS assays! Presentations/Talks AptaFluor™ Methyltransferase Assay: A Homogenous, Universal HMT Assay Based on a Microbial Riboswitch Tuesday, September 20th – 3:15PM Poster
- Published in News
The Advantages Of The Transcreener Phosphodiesterase Assay
Tuesday, 16 August 2016
There are many phosphodiesterase assay kits currently on the market. Comparing the various assays allows pharmaceutical companies to determine for themselves the advantages of using a Transcreener biochemical assay. At BellBrook Labs, located in Madison, WI, we focus on developing HTS assays which can be used to streamline and enhance the drug discovery process. For
- Published in Products
Fighting Infection’s Ghost
Wednesday, 15 June 2016
Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of
- Published in Emerging Targets
Recent Posts
-
One Way to Accelerate Biochemical Assay Development
In vitro biochemical assay development can be a... -
Ubiquitin Ligase Assay: A Handy Tool for Drug Discovery
Can one cellular pathway contribute to many dif... -
Could an Inhibitor of Phosphodiesterase Activity be a Treatment for Alzheimer’s?
As we continue to increase our lifespan, diseas... -
Immuno-Oncology Drug Discovery: A CD39 Activity Assay for a Promising Target
What comes to mind when you think of immunother... -
How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments
As estrogen receptor (ER) positive breast cance...
